Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8197779 | 0.85 | PRKCZ (0.54) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL3796442 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HPGDPRKCZMEN1KMT2A | |
| SCHEMBL26038677 | 0.81 | ALDH1A1 (0.35) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL23927255 | 0.80 | NOTUM (0.40) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL17398237 | 0.80 | NOTUM (0.46) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL26043401 | 0.79 | DAO (0.36) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL1041240 | 0.75 | ALDH1A1 (0.59) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL3709557 | 0.75 | PRKCZ (0.62) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL4116461 | 0.75 | ALDH1A1 (0.57) | ALDH1A1HPGDPRKCZLMNAMEN1 | |
| SCHEMBL23412772 | 0.74 | ALDH1A1 (0.60) | ALDH1A1HPGDPRKCZLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-11-02 | — | — | US | disclosed |
| EP-4139305-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214117-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901151-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | iOmx Therapeutics AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-2744812-B1 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-07-20 | — | — | EP | disclosed |
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2744812-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013024291-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-02-21 | — | — | WO | disclosed |
| WO-2009001214-A2 | THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE, ISOXAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE AND ISOTHIAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001214-A2 | THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE, ISOXAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE AND ISOTHIAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348453-A1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | ABL1, PRKDC, PRKACA | ALDH1A1 2606/4885HPGD 4581/4885PRKCZ 237/4885 |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | HAVCR2, TPMT, PAICS | ALDH1A1 1119/4885HPGD 1690/4885PRKCZ 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.